Lars has more than 25 years of leadership experience in the development of several pharmaceutical products and innovative technologies. Before being appointed to CEO of Engimmune, he was CTO and CEO at Nordic Nanovector, a biotech company developing novel radio-immunoconjugates for treating cancers. Previously, Lars was VP and Strategic Product Lead at Bayer (overseeing Bayer’s biologic pipeline). Before that Lars held several leadership roles at F. Hoffmann-La Roche responsible for clinical operations, clinical supply planning, biologics technology and business development. Lars gained his PhD from the Max-Planck-Institute for Biochemistry, Munich, and Institute for Biochemistry at the University of Zürich; he also holds an executive MBA from the University of St. Gallen, Switzerland.